NEW YORK, Dec. 23, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against BioAge Labs, Inc. (“BioAge” or the “Company”) (NASDAQ: BIOA) on behalf of BioAge stockholders. Our investigation concerns whether BioAge has violated the federal securities laws and/or engaged in other unlawful business practices.

Click here to participate in the action.

The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. BioAge discontinued its STRIDES Phase 2 trial for azelaprag on December 9, 2024, citing safety concerns over elevated liver transaminase levels amongst study participants. The Company had previously highlighted azelaprag's potential for patients undergoing obesity therapy with incretin drugs. Based on this news, shares of BioAge fell by more than 76.8% on the same day.

If you purchased or otherwise acquired BioAge shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Marion Passmore by email at investigations@bespc.com, by telephone at (212) 355-4648, or by filling out this contact form.  There is no cost or obligation to you.

About Bragar Eagel & Squire, P.C.:

Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York and California. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact Information:

Bragar Eagel & Squire, P.C.
Brandon Walker, Esq.
Marion Passmore, Esq.
(212) 355-4648
investigations@bespc.com
www.bespc.com